Daebonglsco.,Ltd Logo

Daebonglsco.,Ltd

Develops raw materials and APIs for the personal care, pharmaceutical, and food industries.

078140 | KO

Overview

Corporate Details

ISIN(s):
KR7078140001
LEI:
Country:
South Korea
Address:
인천광역시 연수구 송도미래로 101 대봉그룹 송도 B&H Plex, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 1980, Daebong LS Co., Ltd. develops, manufactures, and supplies high-quality raw materials for the personal care, pharmaceutical, and food industries. The company specializes in active ingredients for cosmetics and active pharmaceutical ingredients (APIs), leveraging its dedicated research and development centers that focus on convergence technology and natural material applications. Daebong LS provides end-to-end solutions covering the entire business cycle, from raw material sourcing and formulation to final product manufacturing and human application testing. Committed to a mission of enhancing human health and beauty, the company emphasizes innovation, safety, and the development of eco-friendly products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Regulatory News Service
[기재정정]본점소재지변경
Korean 8.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-29 00:00
Regulatory News Service
본점소재지변경
Korean 5.0 KB
2025-07-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.5 KB
2025-06-30 00:00
Regulatory News Service
[기재정정]신규시설투자등
Korean 12.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-04-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.5 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 27.7 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 25.6 KB
2025-03-21 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 525.7 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 14.0 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 152.4 KB
2025-02-17 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 8.9 KB
2025-02-17 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.2 KB
2025-01-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 58.9 KB

Automate Your Workflow. Get a real-time feed of all Daebonglsco.,Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Daebonglsco.,Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Daebonglsco.,Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.